Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

Bibliographic Details
Main Authors:	Jia-Li Xu, Xin-Zhu Wang, Hu-Ning Jiang, Yi Chen, Rong Wang, Yong-Qian Shu, Pei-Fang Wei.
Format:	Article
Language:	English
Published:	Wolters Kluwer 2020-10-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001070

Similar Items

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
by: Ja Yoon Heo, et al.
Published: (2019-11-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
by: Karam Khaddour, et al.
Published: (2020-10-01)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
by: Ryuhjin Ahn, et al.
Published: (2021-03-01)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
by: Ahn, Ryuhjin, et al.
Published: (2021)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
by: Shuai Wang, et al.
Published: (2018-08-01)

An evaluation of the checkpoint kinase inhibitor V158411
by: Stephens, Peter Andrew
Published: (2015)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
by: Caroline Imbert, et al.
Published: (2020-01-01)

Combining gemcitabine with checkpoint kinase inhibitors to sensitize pancreatic tumors
by: Saini, Priyanka
Published: (2015)

Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!
by: Steffen K. Meurer, et al.
Published: (2018-02-01)

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors
by: Abtahi, S., et al.
Published: (2022)

Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
by: Sandeep Kumar, et al.
Published: (2020-01-01)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
by: Liu W, et al.
Published: (2020-07-01)

Commentary: Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!
by: Marius Pollet, et al.
Published: (2018-08-01)

Research Progress of Histone Deacetylase Inhibitor Combined with  Immune Checkpoint Inhibitor in the Treatment of Tumor
by: Chen FANG, et al.
Published: (2021-03-01)

A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.
by: Sankar N Krishna, et al.
Published: (2013-01-01)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
by: Sun Jin, et al.
Published: (2011-03-01)

Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report
by: Periklis Kyriazis, et al.
Published: (2021-04-01)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
by: Regzedmaa O, et al.
Published: (2019-06-01)

Highlights on immune checkpoint inhibitors in non–small cell lung cancer
by: Meng Shen, et al.
Published: (2017-03-01)

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
by: Fang-Fei Qian, et al.
Published: (2020-10-01)

Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of  Small Cell Lung Cancer
by: Benlin HUANG, et al.
Published: (2019-04-01)

Role of immune-checkpoint inhibitors in lung cancer
by: Prantesh Jain, et al.
Published: (2018-01-01)

Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors  of Small Cell Lung Cancer
by: Yaning YANG, et al.
Published: (2020-10-01)

Correction: A Fluorescence-Based Thermal Shift Assay Identifies Inhibitors of Mitogen Activated Protein Kinase Kinase 4
by: Sankar N. Krishna, et al.
Published: (2013-01-01)

Correction: A Fluorescence-Based Thermal Shift Assay Identifies Inhibitors of Mitogen Activated Protein Kinase Kinase 4.
by: Sankar N. Krishna, et al.
Published: (2013-01-01)

Differential effects of mitogen-activated protein kinase pathway inhibitors on P-glycoprotein activation
by: Hirokazu Wakuda, et al.
Published: (2015-03-01)

Inhibitors of Mitogen-Activated Protein Kinases Downregulate COX-2 Expression in Human Chondrocytes
by: Riina Nieminen, et al.
Published: (2005-01-01)

Peptide Based Inhibitors of Protein Binding to the Mitogen-Activated Protein Kinase Docking Groove
by: Anita Alexa, et al.
Published: (2021-07-01)

Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer
by: Hanfei GUO, et al.
Published: (2020-02-01)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
by: Zhenbin Qiu, et al.
Published: (2019-08-01)

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer
by: LI Xiangmin, et al.
Published: (2019-06-01)

Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer
by: Shuang ZHANG, et al.
Published: (2017-09-01)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
by: Junichi Soh, et al.
Published: (2021-08-01)

Research progress in immune checkpoint inhibitors for lung cancer in China
by: Jiadi Gan, et al.
Published: (2021-07-01)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
by: Zhaozhen Wu, et al.
Published: (2021-02-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)
by: Caicun ZHOU, et al.
Published: (2021-04-01)

Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in  Non-small Cell Lung Cancer
by: Peng WANG, et al.
Published: (2021-07-01)

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
by: Nina Zila, et al.
Published: (2018-03-01)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
by: Chengdi Wang, et al.
Published: (2021-08-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)